Biotechnology | Disease | FDA | Neurology | Therapeutics
Amneal Received U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease
On Aug. 7, 2024, Amneal Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) had approved CREXONT…